India's NPPA proposing caps on pharma trade margins
A bigger dose of price control is on the cards with India’s drug price regulator, the National Pharmaceutical Pricing Authority (NPPA), considering a proposal to cap trade margins of all medicines at 30% in a bid to curb profiteering.
The proposal was recently mooted at a closed door meeting between officials of the Prime Minister’s Office and the Department of Pharmaceuticals (DoP), and is said to be among the forerunners to be put in action with the newly elected government assuming office end-May.
A DoP official said: "One major factor that contributes to high drug prices is the unreasonable trade margins." Noting that the matter has been under discussion for a long time, the official said it was included in the interim report of the Sandhu Committee constituted by the Department of Chemical and Petrochemicals in 2004, and subsequently in another report on 'High Trade Margin in the sale of drugs' in 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze